Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment
Desmoid tumor (DT) is a rare, locally aggressive, mesenchymal neoplasm that can arise at any site in the body. Medical therapies play a major role for DT’s patients requiring treatment. A novel systemic approach has recently emerged with Nirogacestat, a γ-secretase inhibitor targeting the NOTCH sign...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
18 Oct 2024
|
| In: |
Expert opinion on pharmacotherapy
Year: 2024, Jahrgang: 25, Heft: 16, Pages: 2115-2124 |
| ISSN: | 1744-7666 |
| DOI: | 10.1080/14656566.2024.2418416 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/14656566.2024.2418416 Verlag, lizenzpflichtig, Volltext: https://www.tandfonline.com/doi/full/10.1080/14656566.2024.2418416 
|
| Verfasserangaben: | Fernando Campos, and Bernd Kasper |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1923815636 | ||
| 003 | DE-627 | ||
| 005 | 20250717012055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250429s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14656566.2024.2418416 |2 doi | |
| 035 | |a (DE-627)1923815636 | ||
| 035 | |a (DE-599)KXP1923815636 | ||
| 035 | |a (OCoLC)1528044909 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Campos, Fernando |e VerfasserIn |0 (DE-588)1364054345 |0 (DE-627)1923816853 |4 aut | |
| 245 | 1 | 0 | |a Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment |c Fernando Campos, and Bernd Kasper |
| 264 | 1 | |c 18 Oct 2024 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.04.2025 | ||
| 520 | |a Desmoid tumor (DT) is a rare, locally aggressive, mesenchymal neoplasm that can arise at any site in the body. Medical therapies play a major role for DT’s patients requiring treatment. A novel systemic approach has recently emerged with Nirogacestat, a γ-secretase inhibitor targeting the NOTCH signaling pathway. Nirogacestat is the first drug in its class to receive approval from the Food and Drug Administration (FDA) and is the first FDA-approved treatment specifically for DTs. We reviewed the data leading to its discovery, including its mechanism of action, pharmacological properties, clinical efficacy, and its positioning within the current treatment armamentarium for DTs. High-quality evidence for systemic therapies in the management of DTs remains an unmet need. Nirogacestat now joins sorafenib as the only drugs with efficacy in DTs demonstrated by randomized phase 3 studies. Currently, there are no comparative trials of the available systemic therapies. Therefore, physicians should consider factors such as drug accessibility, cost, toxicity profile, comorbidities, and patient preferences when selecting treatment. Long-term efficacy and safety data will be essential for evaluating the duration of treatment response and monitoring late-onset side effects of Nirogacestat. | ||
| 650 | 4 | |a aggressive fibromatosis | |
| 650 | 4 | |a desmoid fibromatosis | |
| 650 | 4 | |a Desmoid tumor | |
| 650 | 4 | |a gamma secretase inhibitor | |
| 650 | 4 | |a nirogacestat | |
| 650 | 4 | |a NOTCH pathway | |
| 700 | 1 | |a Kasper, Bernd |d 1974- |e VerfasserIn |0 (DE-588)12274764X |0 (DE-627)082130736 |0 (DE-576)29340447X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on pharmacotherapy |d Abingdon, Oxon : Routledge, Taylor & Francis, 1999 |g 25(2024), 16, Seite 2115-2124 |h Online-Ressource |w (DE-627)324741901 |w (DE-600)2030119-4 |w (DE-576)302969330 |x 1744-7666 |7 nnas |a Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:16 |g pages:2115-2124 |g extent:10 |a Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment |
| 856 | 4 | 0 | |u https://doi.org/10.1080/14656566.2024.2418416 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.tandfonline.com/doi/full/10.1080/14656566.2024.2418416 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250429 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 12274764X |a Kasper, Bernd |m 12274764X:Kasper, Bernd |d 60000 |d 61200 |e 60000PK12274764X |e 61200PK12274764X |k 0/60000/ |k 1/60000/61200/ |p 2 |y j | ||
| 999 | |a KXP-PPN1923815636 |e 4715236680 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment","title":"Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"18 Oct 2024"}],"recId":"1923815636","physDesc":[{"extent":"10 S."}],"id":{"doi":["10.1080/14656566.2024.2418416"],"eki":["1923815636"]},"note":["Gesehen am 29.04.2025"],"relHost":[{"titleAlt":[{"title":"EOP"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"324741901","origin":[{"publisher":"Routledge, Taylor & Francis ; Informa Healthcare","dateIssuedDisp":"1999-","dateIssuedKey":"1999","publisherPlace":"Abingdon, Oxon ; London [u.a.]"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2030119-4"],"issn":["1744-7666"],"eki":["324741901"]},"disp":"Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatmentExpert opinion on pharmacotherapy","title":[{"title":"Expert opinion on pharmacotherapy","subtitle":"EOP","title_sort":"Expert opinion on pharmacotherapy"}],"part":{"issue":"16","pages":"2115-2124","extent":"10","volume":"25","year":"2024","text":"25(2024), 16, Seite 2115-2124"},"language":["eng"],"pubHistory":["1.1999/2000 -"]}],"name":{"displayForm":["Fernando Campos, and Bernd Kasper"]},"person":[{"family":"Campos","display":"Campos, Fernando","role":"aut","given":"Fernando"},{"family":"Kasper","display":"Kasper, Bernd","given":"Bernd","role":"aut"}]} | ||
| SRT | |a CAMPOSFERNEXAMININGN1820 | ||